Pila Pharma enrolls first participant in PP-CT04 obesity trial of XEN-D0501

• Pila Pharma launched dosing for Part 1 of PP-CT04, a 12-week obesity trial of oral candidate XEN-D0501.
• No clinical results have been presented; Part 2 is slated to start once Part 1 clears an internal safety review.
• The study aims to assess safety and tolerability, with additional readouts on drug exposure and efficacy.
• Part 1 uses an eight-participant pilot cohort with intensified safety monitoring before broader enrollment proceeds.
• Dosing uses individual titration to higher target exposures, seeking levels not previously tested in the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.